Table 2 Different therapy in patients with early CD and late CD
Medical treatments | N | Inclusion LI | Follow up LI | P value |
|---|---|---|---|---|
Early CD | ||||
Total | 70 | 6.3 [1.7–10.5] | 3.4 [0.6–7.4] | 0.001 |
IFX | 42 | 5.5 [1.3–12.3] | 2.8 [0.3–7.4] | 0.01 |
Other therapy | 28 | 6.9 [2.8–8.8] | 4.1 [1.4–8.0] | 0.02 |
Steroids + AZA | 11 | 8.1 [6.5–12.8] | 4.4 [1.8–11.0] | 0.02 |
Immunomodulator | 9 | 4.3 [1.8–7.2] | 3.0 [1.8–6.3] | 0.61 |
Enteral nutrition | 2 | 11.0 [6.8–11.0] | 7.4 [1.3–7.4] | 0.18 |
Mesalazine | 6 | 4.9 [0.3–8.1] | 3.6 [0.3–7.5] | 0.50 |
Late CD | ||||
Total | 84 | 5.9 [3.1–11.0] | 5.2 [2.0–10.5] | 0.71 |
IFX | 38 | 6.6 [2.7–13.6] | 6.7 [2.0–12.5] | 0.93 |
Other therapy | 46 | 5.5 [3.2–10.3] | 4.3 [2.0–9.4] | 0.20 |
Steroids + AZA | 14 | 5.0 [3.7–6.5] | 3.3 [2.3–8.4] | 0.39 |
Immunomodulator | 22 | 6.3 [2.9–11.4] | 4.9 [2.3–9.3] | 0.09 |
Enteral nutrition | 7 | 10.6 [2.0–18.3] | 2.4 [1.3–11.9] | 0.71 |
Mesalazine | 3 | 3.2 [1.0–4.9] | 9.0 [1.0–13.2] | 0.18 |